四川大学华西医院2011年老年住院肺癌患者用药分析  

Drug Use Analysis on Over-60-year Inpatients with Lung Cancer in the West China Hospital of Sichuan University in 2011

作　　者：卢静[1] 徐珽[1] 李幼平[2] 吴斌[1] 尹茜[1] 占美[1] 肖桂荣[1] 张莹[1] 

机构地区：[1]四川大学华西医院药剂科,成都610041 [2]四川大学华西医院中国循证医学中心,成都610041

出　　处：《中国循证医学杂志》2014年第10期1171-1178,共8页Chinese Journal of Evidence-based Medicine

基　　金：美国中华医学基金会卫生政策循证研究合作项目(编号:12-095)

摘　　要：目的回顾性分析四川大学华西医院2011年老年（≥60岁）住院肺癌患者的用药情况,并与同期老年门诊肺癌患者比较,分析其用药情况。方法通过四川大学华西医院信息系统提取该院2011年第一诊断为肺癌的老年患者基本信息、用药信息和费用信息,采用Excel 2010软件对用药品种和费用进行统计。结果 1该院2011年老年住院肺癌患者共2215人次,使用抗肿瘤及辅助治疗药物共5类63种,用药总频次12398人次,人均次用药费用774.93元。2用药1-4种的患者占34.31%,用药5-10种的患者占41.9%,用药11-15种的患者占12.63%。3对因治疗中化疗药物占99.45%,顺铂使用人次最多。4对症治疗中镇痛药占66.69%,止咳药占21.33%,预防骨相关事件药物占11.98%。5抗药物不良反应（ADR）治疗中止吐药占55.07%,保胃药占32.63%,保肝药占12.30%。6其他治疗中免疫增强药占59.46%,造血生长因子占25.42%。7中成药中使用人次超过400的有地榆升白片、鸦胆子油乳、艾迪注射液和回生口服液。8在药物单用/联用中,化疗药物两药联用化疗方案占78.38%,镇痛单药治疗占66.21%,保肝单药治疗占83.41%,止吐双药治疗占45.88%,保胃单药治疗占90.53%,免疫增强单药治疗占81.01%,造血生长因子单药治疗占82.31%,中成药单药治疗占37.39%,止咳和预防骨相关事件均为单药治疗。9使用频次前10位的药物依次为泮托拉唑、托烷司琼、昂丹司琼、苯海拉明、胸腺五肽、顺铂、地榆升白片、曲马多、鸦胆子油乳和艾迪注射液。10与门诊治疗相比,住院患者化疗、镇痛、止吐、保胃、保肝和中成药使用频次更高,预防骨相关事件药物使用频次更低,免疫增强药和造血生长因子使用频次相当。结论四川大学华西医院2011年老年住院肺癌患者抗肿瘤治疗以双药和单药化疗方案为主;辅助治疗中镇痛、止吐、保胃治疗比例较大;此外,中成药和免疫增强药常用。Objective To retrospectively investigate the drug use of over-60-year inpatients with lung cancer in the West China Hospital of Sichuan University in 2011, and to compare with outpatients with lung cancer concurrently, so as to evaluate the rationality of drug use among over-60-year inpatients with lung cancer in the West China Hospital. Methods The information of over-60-year inpatients with lung cancer as initial diagnosis in the West China Hospital in 2011 was collected from the hospital information system （HIS）, including patient information, drug use information, cost information, etc. Data rearrangement and analysis by classes and costs were carried out using Microsoft Excel 2010 soft- ware. Results a） There was 2 215 person-times of over-60-year inpatients with lung cancer in the West China Hospital of Sichuan University in 2011. A total of 5 classes, 63 kinds of anti-tumor and adjuvant therapy drugs were involved. The total drug use frequency was 12 398 person-times. The average medicine cost was 774.93 yuan. b） The ratio of patients us- ing 1 to 4 kinds of drugs was 34.31%, 5 to 10 kinds was 41.9%, and 11 to 15 kinds was 12.63%. c） For etiological treatment, the ratio of chemotherapy drugs was 99.45%, and the most used was cisplatin, d） For symptomatic treatment, the ratio of analgesics was 66.69%; the ratio of antitussive drugs was 21.33%; and the ratio of skeletal related events prevention drugs was 11.98%. e） For anti-ADR treatment, the ratio of antiemetic drugs was 55.07%; the ratio of stomach protection drugswas 32.63%; and the ratio of hepatic protection drugs was 12.30%. f） For other treatment, the ratio of immunopotentiat- ing drugs was 59.46%; and the ratio of hematopoietic growth factor was 25.42%. g） For Chinese patent medicine, drugs used over 400 person-times were Diyushengbai tablet, Javanica oil emulsion injection, Aidi injection, and Huisheng oral liquid, h） For single/combined treatment, the ratio of two-drug combined chemotherapy was 78.38%, one analgesics drug treat

关 键 词：肺癌 老年 住院患者 用药分析 四川大学华西医院 

分 类 号：R734.2[医药卫生—肿瘤]